- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04640935
Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC. (AVATAX)
Retrospective Multicenter Study of Paclitaxel in Combination With Bevacizumab in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC).
Обзор исследования
Статус
Условия
Подробное описание
Lung and bronchopulmonary cancer is the leading cause of cancer death in France and worldwide. It is diagnosed at the metastatic stage from the outset in approximately 50% of cases. Non-small cell lung cancers (NSCLC) are the most frequent histological forms of lung cancer (approximately 85% of cases) with a predominance of the non-epidermal type.
The increase in the number of treatments available, improved supportive care and better patient selection have, in recent years, made it possible to expand the range of first-line chemotherapy treatments available at delà̀ and have contributed to the increase in overall survival (OS). As a result, nearly 80% of patients with metastatic NSCLC receive a second line of treatment. The main objective in these often symptomatic patients is a satisfactory tumor control rate with acceptable tolerability.
For a long time, the second-line reference chemotherapy has been docetaxel or pemetrexed as monotherapy with modest results. Alternative treatments such as the combination of paclitaxel (chemotherapy)-bevacizumab (anti-angiogenic monoclonal antibody) have been studied. Since 2010, by analogy with breast cancer and in the absence of therapeutic alternatives, the paclitaxel-bevacizumab doublet has been used in non-epidermal stage IV NSCLC in France. The value of combining taxane chemotherapy with an anti-angiogenic molecule has been demonstrated in two Phase 3 clinical trials. Thus, this combination is an integral part of the possible treatments in 2nd line and beyond, registered since 2016 in the treatment guidelines for non-epidermal NSCLC.
The first-line therapeutic strategy will also be redefined in 2019 with the use of immunotherapy for a majority of patients. Subsequent treatment lines will be modified, with a focus on chemotherapy, in particular the paclitaxel-bevacizumab combination.
As this combination has been used in current practice for several years, and in view of the upcoming changes to the first and second line of NSCLC treatment, data on the efficacy and tolerance of this combination in real life are needed to guide our practices. Recent studies are also looking at the efficacy of chemotherapy, particularly taxane chemotherapy associated with an anti-angiogenic agent after a previous line including immunotherapy, with a favorable signal.
The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
-
Boulogne Billancourt, Франция
- Hopital Ambroise Pare Ap-Hp
-
Brest, Франция
- Centre Hospitalier Universitaire Brest
-
Chambéry, Франция
- Centre Hospitalier Metropole Savoie
-
Créteil, Франция
- Centre Hospitalier Intercommunal de Créteil
-
Grenoble, Франция
- Centre Hospitalier Universitaire Grenoble Alpes
-
Le Chesnay, Франция
- Centre Hospitalier de Versailles André Mignot
-
Lille, Франция
- Centre Hospitalier Universitaire de Lille
-
Lyon, Франция
- Hospices Civils de Lyon
-
Lyon, Франция
- Centre Leon Berard Lyon
-
Mantes-la-Jolie, Франция
- Centre Hospitalier François Quesnay
-
Metz-Tessy, Франция, 74374
- Centre Hospitalier Annecy Genevois
-
Paris, Франция
- Institut Curie
-
Saint-Cloud, Франция
- Institut Curie Saint Cloud
-
Saint-Étienne, Франция
- Institut de Cancérologie Lucien Neuwirth
-
Suresnes, Франция
- Hôpital Foch
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Описание
Inclusion Criteria:
- At least 18 years old;
- Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC;
- Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification;
- Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not;
- Alive patients not opposed to the use of their data
Exclusion Criteria:
- Patient under guardianship or curatorship at the date of the study ;
- Patients alive at the time of the study who are opposed to the use of their data
- Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.
Учебный план
Как устроено исследование?
Детали дизайна
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-free survival
Временное ограничение: Up to 12 months
|
Progression-free survival with paclitaxel-bevacizumab, i.e., the time from the start of paclitaxel-bevacizumab treatment to cancer progression, estimated at 12 months in the general population.
|
Up to 12 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Drugs administration dosage description
Временное ограничение: Up to 12 months
|
Description of the different monthly drug administration regimens
|
Up to 12 months
|
|
Objective response rate and control rate
Временное ограничение: Up to 12 months
|
Objective response rate and control rate according to RECIST 1.1 criteria in the general population
|
Up to 12 months
|
|
Overall survival Rate
Временное ограничение: Up to 12 months
|
Overall survival, assessed on the whole population
|
Up to 12 months
|
|
Objective Response Rate
Временное ограничение: Up to 12 months
|
Objective Response Rate in the following subgroups:
|
Up to 12 months
|
|
Progression-Free Survival Rate
Временное ограничение: Up to 12 months
|
Progression-Free Survival in the following subgroups:
|
Up to 12 months
|
|
Disease Control Rate
Временное ограничение: Up to 12 months
|
Disease Control in the following subgroups:
|
Up to 12 months
|
|
Overall Survival Rate
Временное ограничение: Up to 12 months
|
Overall Survival in the following subgroups:
|
Up to 12 months
|
|
Frequency of safety events
Временное ограничение: Up to 12 months
|
Frequency of grade ≥3 adverse events and frequency of discontinuation of paclitaxel-bevacizumab for toxicity ;
|
Up to 12 months
|
Соавторы и исследователи
Соавторы
Следователи
- Главный следователь: Chantal Decroisette, CH Annecy Genevois
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 19-09
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .